Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
about
Switching treatments in haemophilia: is there a risk of inhibitor development?Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIIICost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia ATuroctocog alfa: an evidence-based review of its potential in the treatment of hemophilia APractical aspects of extended half-life products for the treatment of haemophilia
P2860
Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antihemophilic factor (recombi ...... in patients with hemophilia A
@en
type
label
Antihemophilic factor (recombi ...... in patients with hemophilia A
@en
prefLabel
Antihemophilic factor (recombi ...... in patients with hemophilia A
@en
P2860
P356
P1476
Antihemophilic factor (recombi ...... in patients with hemophilia A
@en
P2093
Steven Pipe
P2860
P304
P356
10.2147/BTT.2009.2872
P577
2009-07-13T00:00:00Z